Education
About Us
Working with TipRanks
Follow Us
Santen Pharmaceutical Co Ltd (SNPHF)
OTHER OTC:SNPHF
Total Valuation
Santen Pharmaceutical Co has a market cap or net worth of $3.35B. The enterprise value is $513.05B.
Market Cap$3.35B
Enterprise Value$513.05B
Share Statistics
Santen Pharmaceutical Co has 322,268,550 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding322,268,550
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Santen Pharmaceutical Co’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 13.04%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)13.04%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee80.13M
Profits Per Employee9.68M
Employee Count3,744
Asset Turnover0.73
Inventory Turnover2.50
Valuation Ratios
The current PE Ratio of Santen Pharmaceutical Co is 16.9. Santen Pharmaceutical Co’s PEG ratio is 0.32.
PE Ratio16.9
PS Ratio1.65
PB Ratio1.73
Price to Fair Value1.73
Price to FCF9.11
Price to Operating Cash Flow11.62
PEG Ratio0.32
Income Statement
In the last 12 months, Santen Pharmaceutical Co had revenue of 300.00B and earned 36.25B in profits. Earnings per share was 103.98.
Revenue300.00B
Gross Profit171.03B
Operating Income56.23B
Pretax Income47.48B
Net Income36.25B
EBITDA68.83B
Earnings Per Share (EPS)103.98
Cash Flow
In the last 12 months, operating cash flow was 46.19B and capital expenditures -7.37B, giving a free cash flow of 38.82B billion.
Operating Cash Flow46.19B
Free Cash Flow38.82B
Free Cash Flow per Share120.46
Dividends & Yields
Santen Pharmaceutical Co pays an annual dividend of $0.123, resulting in a dividend yield of 2.47%
Dividend Per Share$0.123
Dividend Yield2.47%
Payout Ratio83.46%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.09
52-Week Price Change7.61%
50-Day Moving Average10.02
200-Day Moving Average10.49
Relative Strength Index (RSI)57.82
Average Volume (3m)0.00
Important Dates
Santen Pharmaceutical Co upcoming earnings date is Feb 5, 2026, TBA (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateFeb 5, 2026
Ex-Dividend Date―
Financial Position
Santen Pharmaceutical Co as a current ratio of 2.58, with Debt / Equity ratio of 12.97%
Current Ratio2.58
Quick Ratio1.99
Debt to Market Cap0.06
Net Debt to EBITDA-0.85
Interest Coverage Ratio20.70
Taxes
In the past 12 months, Santen Pharmaceutical Co has paid 11.63B in taxes.
Income Tax11.63B
Effective Tax Rate0.24
Enterprise Valuation
Santen Pharmaceutical Co EV to EBITDA ratio is 6.33, with an EV/FCF ratio of 8.03.
EV to Sales1.45
EV to EBITDA6.33
EV to Free Cash Flow8.03
EV to Operating Cash Flow7.15
Balance Sheet
Santen Pharmaceutical Co has $66.08B in cash and marketable securities with $35.63B in debt, giving a net cash position of $30.46B billion.
Cash & Marketable Securities$66.08B
Total Debt$35.63B
Net Cash$30.46B
Net Cash Per Share$94.51
Tangible Book Value Per Share$601.58
Margins
Gross margin is 55.20%, with operating margin of 18.74%, and net profit margin of 12.08%.
Gross Margin55.20%
Operating Margin18.74%
Pretax Margin15.83%
Net Profit Margin12.08%
EBITDA Margin22.94%
EBIT Margin16.96%
Analyst Forecast
The average price target for Santen Pharmaceutical Co is $14.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$14.13
Price Target Upside33.29% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―